Evidence map›Paper›PMID 37214958›Full record

ArticlebioRxiv : the preprint server for biology2023

SKP2 knockout in Rb1/p53 deficient mouse models of osteosarcoma induces immune infiltration and drives a transcriptional program with a favorable prognosis.

Alexander Ferrena, Jichuan Wang, Ranxin Zhang, Burcu Karadal-Ferrena, Waleed Al-Hardan, Swapnil Singh, Hasibagan Borjihan, Edward Schwartz, Hongling Zhao, Rui Yang and 3 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Alexander FerrenaInstitute for Clinical and Translational Research, Albert Einstein College of Medicine, Bronx, NY, USA.
Jichuan WangDepartment of Orthopedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Ranxin ZhangDepartment of Orthopedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Burcu Karadal-FerrenaDepartment of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.
Waleed Al-HardanDepartment of Orthopedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Swapnil SinghDepartment of Orthopedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Hasibagan BorjihanDepartment of Orthopedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Edward SchwartzDepartment of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA.
Hongling ZhaoDepartment of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
Rui YangDepartment of Orthopedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
David GellerDepartment of Orthopedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Bang HoangDepartment of Orthopedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Deyou ZhengDepartment of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA.
Albert Einstein College of Medicine · US

Funding

Core-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3M
Leveraging Tumor Suppressor Inactivation for Osteosarcoma TherapyR01CA255643 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI HOANG, BANG H · 2021 to 2024
$1.7M
NRSA Training CoreTL1TR002557 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI MARANTZ, PAUL R · 2018 to 2022
$1.0M
NCATS NIH HHS TL1 TR002557NCATS NIH HHS UL1 TR001073NCI NIH HHS R01 CA255643
6 · The paper itself

Abstract

Purpose: Osteosarcoma (OS) is an aggressive bone malignancy with a poor prognosis. One putative proto-oncogene in OS is Experimental Design: We performed RNA-sequencing (RNA-seq) on tumors from a transgenic OS mouse model with conditional Results: We found large differences in gene expression after SKP2 knockout. Strikingly, we observed increased expression of genes related to immune microenvironment infiltration in TKO tumors. We observed significant increases in signature genes for macrophages and to a lesser extent, T cells, B cells and vascular cells. We also uncovered a set of relevant transcription factors that may mediate the changes. In OS patient cohorts, high expression of genes upregulated in TKO was correlated with favorable overall survival, which was largely explained by the macrophage gene signatures. This relationship was further supported by our finding that SKP2 expression was negatively correlated with macrophage infiltration in the NCI-TARGET OS and the TCGA Sarcoma cohort. Conclusion: Our findings indicate that SKP2 may mediate immune exclusion from the OS tumor microenvironment, suggesting that SKP2 modulation in OS may induce anti-tumor immune activation.

Indexed as

Immune infiltrationOsteosarcomaRNA-seqSKP2TME

Identifiers

PMID37214958
PMCPMC10197654
OpenAlexW4376272133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.